GARDP Request for Proposal for Cost of Goods Sold modelling for antibiotics for SECURE Initiative

SECURE will increase access to a portfolio of quality-assured antibiotics in a sustainable, equitable and appropriate way. The antibiotic portfolio will be adapted to national public health and clinical needs and will include both existing antibiotics and new antibiotics, where access has been limited because of affordability, recurrent shortages or other market challenges.

GARDP would like to better understand the Cost of Goods Sold (COGs) to support GARDP’s plans for access, manufacturer selection, market shaping, and product optimization, especially for its product range. Additionally, GARDP is interested if there are potential process improvements across input raw material costs, yields, processing times, and facility parameters.

If you are interested to receive complete documentation of this RFP, please send a request to: RFP_Procurement@gardp.org.

Closing date: October 20th 2023

GARDP Request for Proposal for the Assessment of AMR Dx and Abx Use in India

GARDP and FIND together is planning to implement the project to identify the existing gaps in the present AMR but also wants to work closely with the Institutes and KOL’s to create pathways to introduce newer antibiotics in the system.

The aim of this project is to assess AMR laboratory capacity, antibiotic use and existing Stewardship practices to prepare for introduction of cefiderocol (and other antibiotics) and new low blood culture and molecular point of care treatment platforms in Kenya and India. To define a go to market strategy for the AMR products, there’s need for a better understanding of current practices at both private and public hospitals at high/quaternary, tertiary and district level, in the selected countries.

If you are interested to receive complete documentation of this RFP, please send a request to: RFP_Procurement@gardp.org.

Closing date: October 13th 2023

GARDP Request for Proposal for SECURE seeking for a Consultant Review of Regulatory Authorities role to address Antibiotic Shortages in Low and Middle Income Countries

SECURE is a collaborative project from GARDP and the WHO which will increase access to a portfolio of quality-assured antibiotics in a sustainable, equitable and appropriate way. The antibiotic portfolio will be adapted to national public health and clinical needs and will include both existing antibiotics and new antibiotics, where access has been limited because of affordability, recurrent shortages or other market challenges.

GARDP and SECURE seek a consultant, consulting agency, or group of consultants to help landscape activities that select NRAs in low- and middle-income countries (LMICs) are undertaking to address shortages, identify best practices, and support planning for a technical consultation on the role of NRAs to address medication shortages, with a focus on antibiotics.

If you are interested to receive complete documentation of this RFP, please send a request to: RFP_Procurement@gardp.org.

Closing date: October 13th 2023

GARDP Request for Proposal for Development of an antibiotic forecasting model for SECURE

SECURE will increase access to a portfolio of quality-assured antibiotics in a sustainable, equitable and appropriate way. The antibiotic portfolio will be adapted to national public health and clinical needs and will include both existing antibiotics and new antibiotics, where access has been limited because of affordability, recurrent shortages or other market challenges.

Lack of a strong forecasting model hampers the ability of countries and other procurers to ensure consistent access to priority antibiotics. In addition, a key intervention by SECURE will be to establish and support pooled or coordinated procurement mechanisms with an existing procurement entity for antibiotics by aggregating demand across multiple countries. The creation of an antibiotic forecasting model to support both national or individual buyer planning as well as pooling, stockpiling and contracting with suppliers using a prioritized portfolio of antibiotics is therefore an essential component of the procurement mechanism.

If you are interested to receive complete documentation of this RFP, please send a request to: RFP_Procurement@gardp.org.

Closing date: October 6th 2023

GARDP Request for Proposal Zoli POP PK modeling

GARDP has entered in collaboration agreement with Innoviva Specialty Therapeutics (IST), formerly known as Entasis therapeutics for the development of Zoliflodacin. Zoliflodacin (ETX0914) is a new promising option to address the risk posed by drug[1]resistant gonorrhoea. The drug belongs to a new class of antibiotics with a novel mode of action that inhibits bacterial deoxyribonucleic acid (DNA) replication and demonstrated in vitro activity against drug resistant strains of NG. It offers many of the preferred characteristics for gonorrhoea therapy, including single dose oral therapy, low rate of side effects. It is currently the only novel drug targeting exclusively gonorrhoea, in late-stage development / pre-introduction phase in the world. The purpose of this RFP is to find a Contract Research Organization (CRO) that can provide pharmacometrics support for Zoliflodacin new drug approval. The overarching goal of this project is to select a safe and efficacious dose of Zoliflodacin as supportive evidence to the Phase 3 trial results.

If you are interested to receive complete documentation of this RFP, please send a request to: RFP_Procurement@gardp.org.

Closing date: August 25th 2023